Dementia risk in type 2 diabetes varies by treatment, with some metformin-based combination therapies offering greater protection.

IMPACT-HTN, a novel initiative to modernize hypertension care, has been launched by Idorsia at Stanford Hypertension Center and Duke Heart Center.

Risk reductions were stronger in those with psoriasis vs those with obesity or type 2 diabetes without psoriasis.

Adults with SAPHO-CNO experience significantly reduced HRQOL, with scores comparable to those reported in other chronic rheumatic and inflammatory diseases.

While colchicine showed efficacy among most patients with SURF, PFAPA-like features were associated with treatment resistance.

Almost all adults have nonoptimal levels of one or more traditional risk factors before being diagnosed with cardiovascular disease (CVD).

Antithymocyte globulin (ATG) 2.5 and 0.5 mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes.

Two-year follow-up shows a loss of therapeutic benefit when baricitinib treatment is stopped in type 1 diabetes (T1D).

Hypothyroidism was associated with an increased risk for small intestinal bacterial overgrowth across sexes, age groups, and BMI categories.

Insulin resistance severity measured via eGDR enhanced the predictive value of clinical models for cardiovascular disease risk in CKM syndrome.

The FDA has removed the REMS requirement for Caprelsa (vandetanib), a kinase inhibitor for medullary thyroid cancer.

The rate of allogeneic blood transfusion has decreased in patients with RA receiving LEJR, though transfusion remains associated with postoperative complications.